Viewpoints

Crizotinib Provides Benefit for ALK-Rearranged NSCLC with Brain Metastases

Crizotinib Provides Benefit for ALK-Rearranged NSCLC with Brain Metastases

A retrospective analysis of crizotinib data demonstrates control in advanced, metastatic disease, although brain metastases continued to progress.

Metformin Does Not Reduce Lung Cancer Risk

Metformin Does Not Reduce Lung Cancer Risk

A large, retrospective cohort study found no evidence that metformin prevents lung cancer, although nonsmokers may find some benefit.

Feature Articles

The Use of Pharmacogenomics for Selection of Therapy in Non-Small-Cell Lung Cancer

The Use of Pharmacogenomics for Selection of Therapy in Non-Small-Cell Lung Cancer

[Clinical Medicine Insights: Oncology] Performance status is the only known clinical predictor of outcome in patients with advanced non-small-cell lung cancer (NSCLC), but pharmacogenomic markers may also correlate with outcome. This study attempts to correlate clinical and pharmacogenomic measures with overall survival.

Lung Cancer Resources

More Lung Cancer Information

Where to Get Help to Quit Smoking

Patients can learn how to quick smoking cigarettes with the resources found in this informational fact sheet.

Smokeless Tobacco Effects, Harms and Cancer Risk

This patient fact sheet addresses common questions about the harms of smokeless, chewing tobacco.

Cigar Smoking Effects, Harms, and Cancer Risk

This fact sheets answers common questions, risks and health concerns for cigar smoking and cancer.

Lung Cancer: New Resources in Treatment Decision-Making

This fact sheet contains information on the different types of tumors as well as an overview of available biomarker tests.

XALKORI® (crizotinib) for Locally Advanced or Metastatic ALK+ NSCLC

XALKORI® (crizotinib) for Locally Advanced or Metastatic ALK+ NSCLC

This slideshow reviews drug information for XALKORI® (crizotinib), indicated for locally advanced or metastatic ALK+NSCLC.

Table of Contents

Slide 3: Indication, Dosage, ...

ZYKADIA™ (ceritinib)

ZYKADIA™ (ceritinib)

This slideshow reviews drug information for ZYKADIA™ (ceritinib), indicated for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).

Table ...

Abraxane® (paclitaxel protein-bound particles) (albumin-bound) for NSCLC

Abraxane® (paclitaxel protein-bound particles) (albumin-bound) for NSCLC

This slideshow reviews Abraxane® (paclitaxel protein-bound particles (albumin-bound) for patients with non-small cell lung cancer.

Table of Contents

Slide 3: Indication, Dosage, ...

Advanced NSCLC: Best Treatment Option

Advanced NSCLC: Best Treatment Option

By Sandra Cuellar, PharmD, BCOP

A 63-year-old male is referred by his primary care physician for work-up of possible lung cancer. ...

A Rare Cause of Intestinal Dysmotility in a Patient with Small Cell Lung Cancer

A Rare Cause of Intestinal Dysmotility in a Patient with Small Cell Lung Cancer

By Tara Morrison, MD; Yu-Ning Wong, MD, MSCE

A 66-year-old African American man presented with a several month history of weight ...

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs